Impax Asset Management Group plc Has $12.47 Million Stock Holdings in Elevance Health, Inc. (NYSE:ELV)

Impax Asset Management Group plc increased its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 12.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,670 shares of the company's stock after acquiring an additional 3,074 shares during the quarter. Impax Asset Management Group plc's holdings in Elevance Health were worth $12,470,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Norges Bank acquired a new stake in Elevance Health during the fourth quarter worth $1,135,014,000. Wellington Management Group LLP boosted its stake in Elevance Health by 42.5% in the 4th quarter. Wellington Management Group LLP now owns 6,355,532 shares of the company's stock valued at $2,344,556,000 after buying an additional 1,893,947 shares in the last quarter. GAMMA Investing LLC raised its stake in Elevance Health by 81,726.5% during the first quarter. GAMMA Investing LLC now owns 1,474,514 shares of the company's stock worth $641,355,000 after acquiring an additional 1,472,712 shares in the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of Elevance Health by 47.6% during the fourth quarter. First Eagle Investment Management LLC now owns 3,225,339 shares of the company's stock valued at $1,189,828,000 after acquiring an additional 1,039,612 shares during the period. Finally, Orion Portfolio Solutions LLC boosted its stake in shares of Elevance Health by 6,817.8% in the 4th quarter. Orion Portfolio Solutions LLC now owns 908,795 shares of the company's stock valued at $335,254,000 after purchasing an additional 895,658 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company's stock.

Insider Buying and Selling

In other Elevance Health news, CFO Mark Kaye sold 4,588 shares of the business's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the sale, the chief financial officer directly owned 18,977 shares of the company's stock, valued at $8,061,809.14. The trade was a 19.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ELV shares. Truist Financial set a $500.00 price objective on Elevance Health and gave the stock a "buy" rating in a research note on Monday, June 9th. Sanford C. Bernstein reissued an "outperform" rating on shares of Elevance Health in a report on Friday, March 28th. Baird R W downgraded shares of Elevance Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 15th. Cantor Fitzgerald reissued an "overweight" rating and set a $485.00 price target on shares of Elevance Health in a research note on Wednesday, April 23rd. Finally, Mizuho raised their price target on shares of Elevance Health from $455.00 to $505.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, Elevance Health presently has an average rating of "Moderate Buy" and an average target price of $498.87.

Elevance Health Stock Down 0.3%

ELV traded down $1.08 during trading on Monday, reaching $346.76. The company had a trading volume of 2,255,777 shares, compared to its average volume of 1,612,991. The business's fifty day moving average price is $387.65 and its 200 day moving average price is $398.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.43 and a quick ratio of 1.43. Elevance Health, Inc. has a 12 month low of $343.83 and a 12 month high of $567.26. The company has a market cap of $78.34 billion, a P/E ratio of 10.14, a PEG ratio of 0.88 and a beta of 0.60.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.60 by $1.37. The firm had revenue of $48.77 billion for the quarter, compared to the consensus estimate of $46.26 billion. Elevance Health had a return on equity of 18.61% and a net margin of 3.23%. Equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were given a $1.71 dividend. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date of this dividend was Tuesday, June 10th. Elevance Health's dividend payout ratio is presently 26.69%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.